Phio Pharmaceuticals

Coming – April 15

Nobel Prize Winning Science Takes On Skin Cancer

Date and Time

April 15

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Phio Pharmaceuticals (NASDAQ: PHIO) is a clinical stage biotechnology company co-founded by the scientist who was awarded the Nobel prize in 2006 for his discovery of RNAi. RNAi is precision targeted immuno-oncology therapy which has broad applications, across multiple cell types. Phio’s proprietary siRNA platform INTASYL®, derived from RNAi is the only self-delivering siRNA focused on immuno-oncology therapeutics.

Unlike many cancer drugs that flood the entire body, Phio’s lead program (PH-762), targeting early stage cutaneous squamous cell carcinoma (cSCC), is injected directly into the tumor. This dramatically improves patient safety and tolerability, virtually eliminating serious side effects typically seen with systemic immunotherapies.

It has also delivered promising clinical data in skin cancer. Some patients have shown complete or near-complete cancer clearance in a short timeframe, with no serious toxicities reported to date, in other words, a favorable safety profile. Significantly, there is no FDA-approved drug for early-stage cSCC which is the 2nd largest incidence of solid tumors—surgery is the default standard of care—presenting both a significant unmet need and market opportunity.

Register to reserve your space for this fascinating fireside chat on the future of oncology with Phio Pharma President & CEO, Robert Bitterman.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.